NASDAQ: SEEL - Seelos Therapeutics, Inc.

Yield per half year: -45.83%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Seelos Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.

more details
The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1999-04-19
ISIN US81577F1093
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://seelostherapeutics.com
Цена ао 0.39
Change price per day: 0% (0.39)
Change price per week: 0% (0.39)
Change price per month: 0% (0.39)
Change price per 3 month: 0% (0.39)
Change price per half year: -45.83% (0.72)
Change price per year: -83.2% (2.3216)
Change price per 3 year: -23.21% (0.5079)
Change price per 5 year: -18.58% (0.479)
Change price per year to date: 0% (0.39)
All parameters

Underestimation

Title Value Grade
P/S 3.47 5
P/BV -0.2281 0
P/E 0 0
EV/EBITDA -0.4668 0
Total: 4.25

Efficiency

Title Value Grade
ROA, % -699.19 0
ROE, % 113.05 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3518 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % -61.77 0
Yield Ebitda, % 38.03 5
Yield EPS, % 118.38 10
Total: 3.8
More

Institutions Volume Share, %
Sabby Management, LLC 393091 0.24
Gendell, Jeffrey L. 224818 0.14
Vanguard Group Inc 172423 0.11
Wealth Effects LLC 120174 0.07
Blackrock Inc. 56466 0.03
Modera Wealth Management, LLC 40792 0.03
Geode Capital Management, LLC 40390 0.03
Mirae Asset Global Investments Co., Ltd. 29992 0.02
Woodline Partners LP 24152 0.01
Osaic Holdings Inc 21464 0.01



Head Job title Payment Year of birth
Mr. Anthony Marciano Chief Communications Officer N/A
Gopal Krishna Ph.D. Head of Manufacturing & Technical Operations N/A
Tim Whitaker M.D. Chief Medical Officer N/A
Ms. Karen Fusaro Senior VP & Head of Clinical Operations N/A

Address: United States, New York. NY, 300 Park Avenue - open in Google maps, open in Yandex maps
Website: https://seelostherapeutics.com